论文部分内容阅读
迭氮胸腺嘧啶核甙(azidothymidine)(AZT)现用于治疗人免疫缺陷病毒(HIV)感染。它不仅能降低血清病毒滴度,还能使血清反应阳性转阴,并可降低病毒的传播。目前发现,HIV阳性的母亲生出的婴儿在其早期血清反应阳性者高达25～60%。当AZT用于治疗孕妇HIV感染时,该药是否能从母体经胎盘转运到胎儿的文献报道尚未见到。本实验用大鼠模型研究和评价该药的胎盘转运。选用妊娠第18天的朗-伊凡斯(Long-Evans)纯系大鼠。口服30mg/kg AZT。给药后0.5、0.75、1.0、1.5、2.0、4.0及6.0小时断头处死,同时收集母体血液,剖腹取出胎仔和胎盘,三种样本经处理后用高压液相法测定其所含药物浓度。
Azidothymidine (AZT) is currently used to treat human immunodeficiency virus (HIV) infection. It not only reduces serum virus titer, but also makes the seropositive negative, and can reduce the spread of the virus. It has been found that HIV-positive mothers give up to 25-60% of infants with early-stage seropositivity. When AZT is used to treat HIV infection in pregnant women, the literature has not yet seen whether the drug can be transferred from the mother through the placenta to the fetus. In this study, we used rat model to study and evaluate the placental transport of this drug. Eighteen days of gestation, Long-Evans purebred rats were used. Oral 30 mg / kg AZT. The rats were sacrificed at 0.5,0.75,1.0,1.5,2.0,4.0 and 6.0 hours after the administration, meanwhile maternal blood was collected. The fetuses and placenta were removed by cesarean section. The three samples were processed and determined by HPLC.